30.08.2017 21:42:00
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bio-Techne Corporation - TECH
NEW YORK, Aug. 30, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bio-Techne Corporation ("Bio-Techne" or the "Company") (NASDAQ: TECH). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether Bio-Techne and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here to join a class action]
On August 29, 2017, Bio-Techne announced that the Company would be unable to timely file its Annual Report for the fiscal year ended June 30, 2017, citing the "greater-than-anticipated time, resources and effort required to complete work related to the assessment of the Company's internal control over financial reporting." Having identified material weaknesses in internal controls at the end of the prior fiscal year, Bio-Techne advised investors that "[t]he Company believes it has made significant progress in changing the design of our controls as of June 30, 2017; however, the Company believes that material weaknesses still remain within some aspects of its internal control framework."
On this news, Bio-Techne's share price has fallen as much as $1.48, or 1.21%, during intraday trading on August 30, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-bio-techne-corporation---tech-300511773.html
SOURCE Pomerantz LLP
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Bio-Techne Corpmehr Nachrichten
21.11.24 |
S&P 500-Papier Bio-Techne-Aktie: So viel hätte eine Investition in Bio-Techne von vor einem Jahr abgeworfen (finanzen.at) | |
14.11.24 |
S&P 500-Titel Bio-Techne-Aktie: So viel Gewinn hätte ein Bio-Techne-Investment von vor 10 Jahren eingefahren (finanzen.at) | |
07.11.24 |
S&P 500-Titel Bio-Techne-Aktie: So viel hätten Anleger mit einem Investment in Bio-Techne von vor 5 Jahren verdient (finanzen.at) | |
31.10.24 |
S&P 500-Titel Bio-Techne-Aktie: So viel Verlust wäre bei einem Investment in Bio-Techne von vor 3 Jahren angefallen (finanzen.at) | |
30.10.24 |
Schwache Performance in New York: S&P 500 präsentiert sich zum Handelsende schwächer (finanzen.at) | |
30.10.24 |
S&P 500-Handel aktuell: So entwickelt sich der S&P 500 aktuell (finanzen.at) | |
30.10.24 |
Pluszeichen in New York: Börsianer lassen S&P 500 zum Start steigen (finanzen.at) | |
29.10.24 |
Ausblick: Bio-Techne stellt Zahlen zum jüngsten Quartal vor (finanzen.net) |